Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer

NCT05458674 is registered in ClinicalTrials.gov with Criterium, Inc. as lead sponsor.

NCT NCT05458674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05458674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Lead sponsor
Criterium, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 30, 2024
Completion date
August 1, 2027
Enrollment
17 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, pretreated unresectable locally advanced or metastatic her2+ breast cancer